GH Research (NASDAQ:GHRS) Price Target Increased to $31.00 by Analysts at Canaccord Genuity Group

GH Research (NASDAQ:GHRS) had its price objective lifted by equities research analysts at Canaccord Genuity Group from $30.00 to $31.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price would indicate a potential upside of 162.93% from the stock’s current price.

GHRS has been the topic of a number of other reports. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of GH Research in a research note on Monday, March 4th. JMP Securities reduced their price objective on shares of GH Research from $50.00 to $39.00 and set a “market outperform” rating on the stock in a research note on Friday, March 1st.

GH Research Stock Performance

Shares of GHRS stock traded up $0.11 on Monday, hitting $11.79. The stock had a trading volume of 24,175 shares, compared to its average volume of 126,379. The firm has a market capitalization of $613.43 million, a price-to-earnings ratio of -19.02 and a beta of 0.80. The stock’s 50 day moving average is $10.37 and its 200-day moving average is $8.01. GH Research has a 52-week low of $5.05 and a 52-week high of $14.64.

GH Research (NASDAQ:GHRS) last announced its earnings results on Thursday, February 29th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.01). Equities analysts expect that GH Research will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. PEAK6 Investments LLC lifted its position in shares of GH Research by 72.9% in the 3rd quarter. PEAK6 Investments LLC now owns 40,308 shares of the company’s stock worth $405,000 after buying an additional 16,991 shares during the last quarter. AdvisorShares Investments LLC lifted its position in shares of GH Research by 4.3% in the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after buying an additional 1,977 shares during the last quarter. Barclays PLC lifted its position in shares of GH Research by 98.2% in the 3rd quarter. Barclays PLC now owns 63,590 shares of the company’s stock worth $640,000 after buying an additional 31,500 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in shares of GH Research by 16.2% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 92,784 shares of the company’s stock worth $932,000 after buying an additional 12,911 shares during the last quarter. Finally, Lynx1 Capital Management LP lifted its position in shares of GH Research by 13.8% in the 3rd quarter. Lynx1 Capital Management LP now owns 1,103,178 shares of the company’s stock worth $11,087,000 after buying an additional 133,804 shares during the last quarter. 56.90% of the stock is currently owned by institutional investors.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).